{
    "nct_id": "NCT02859207",
    "title": "An Open-Label Parallel-Group Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects",
    "status": "COMPLETED",
    "last_update_time": "2017-06-07",
    "description_brief": "The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Elenbecestat (E2609) \u2014 BACE (beta-secretase) inhibitor, small-molecule"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial title and objective specify a PK study of E2609 (single-dose, hepatic impairment), indicating the intervention is the investigational drug E2609 rather than a diagnostic or non-therapeutic procedure. \ue200cite\ue202turn0search1\ue201.",
        "Act: Web search identifies E2609 as elenbecestat, a BACE (beta-secretase) inhibitor developed by Eisai; BACE inhibitors are small-molecule drugs that target amyloid-beta production (Alzheimer's disease pathology). \ue200cite\ue202turn0search6\ue202turn0search2\ue201.",
        "Act (supporting preclinical/clinical evidence): Preclinical and early clinical reports show E2609 engages BACE1 and reduces A\u03b2 biomarker levels in CSF/plasma, consistent with disease-targeting (anti-amyloid) mechanism. \ue200cite\ue202turn0search0\ue202turn0search3\ue201.",
        "Reflect: Because elenbecestat (E2609) is a small-molecule BACE inhibitor that targets amyloid production (disease pathology), the correct category is 'disease-targeted small molecule'. The study described is a PK/hepatic-impairment study (not a cognitive-only or neuropsychiatric symptom study), so other categories do not apply. \ue200cite\ue202turn0search1\ue202turn0search6\ue201.",
        "Web search results (sources used):",
        "- NCT02859207 \u2014 Trial record titled 'An Open-Label Parallel-Group Study to Evaluate the Pharmacokinetics of E2609...' (PK in mild/moderate hepatic impairment). \ue200cite\ue202turn0search1\ue201.",
        "- Health Research Authority summary \u2014 identifies E2609 as elenbecestat and describes Phase 3/efficacy program in early AD. \ue200cite\ue202turn0search2\ue201.",
        "- Eisai press release \u2014 describes E2609 (elenbecestat) as a BACE inhibitor (development program, Fast Track). \ue200cite\ue202turn0search6\ue201.",
        "- CTAD / press reports and posters \u2014 show pharmacodynamic biomarker effects (reduced A\u03b2, BACE1 engagement) in preclinical/clinical studies of E2609. \ue200cite\ue202turn0search0\ue202turn0search3\ue201."
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational drug E2609 (elenbecestat) is a small\u2011molecule inhibitor of BACE (beta\u2011secretase), an enzyme required for production of amyloid\u2011beta (A\u03b2). BACE inhibition reduces A\u03b2 generation and is therefore an anti\u2011amyloid disease\u2011modifying approach. \ue200cite\ue202turn0search6\ue202turn0search3\ue201",
        "Act: The trial description is a PK/hepatic\u2011impairment study of E2609 (elenbecestat), and publicly available sources identify E2609 as elenbecestat, an oral BACE inhibitor developed by Eisai (partnered with Biogen). Clinical and preclinical reports show E2609 engages BACE1 and lowers A\u03b2 biomarkers (CSF/plasma and amyloid\u2011PET). Relevant records include the Phase 1/2 reports and the PK study record (NCT02859207). \ue200cite\ue202turn1search2\ue202turn0search6\ue202turn0search3\ue201",
        "Reflect: Given the explicit mechanism (BACE inhibition \u2192 decreased A\u03b2 production) the most specific CADRO category is A) Amyloid beta. The trial itself is a pharmacokinetic/hepatic\u2011impairment study (not a diagnostic), but classification is by the drug target/mechanism, so other CADRO categories (e.g., inflammation, tau, synaptic plasticity) do not apply. Note: Phase\u2011III development of elenbecestat was later discontinued for safety/risk\u2011benefit reasons, but that does not change the mechanistic classification. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Web sources used:",
        "- Eisai news release describing elenbecestat (E2609) as a BACE (beta amyloid cleaving enzyme) inhibitor and Phase II results. \ue200cite\ue202turn0search6\ue201",
        "- CTAD / Eisai presentation summarizing clinical biomarker effects (CSF/plasma A\u03b2 reductions) for E2609. \ue200cite\ue202turn0search3\ue201",
        "- Biogen / press releases about discontinuation of Phase III MISSION AD studies (safety/risk\u2011benefit context). \ue200cite\ue202turn0search1\ue201",
        "- Clinical trial record for the PK/hepatic impairment study NCT02859207 (trial of E2609). \ue200cite\ue202turn1search2\ue202turn1search3\ue201"
    ]
}